hypothalamic obesity

Rhythm Pharmaceuticals presented strong clinical data at ENDO 2025 for its obesity drugs targeting acquired hypothalamic obesity. The Phase 3 TRANSCEND trial showed setmelanotide achieved a robust 19.8% placebo-adjusted BMI reduction, consistent across ages and genders, including significant effects when combined with GLP-1 therapies (25.1% reduction). Pediatric patients had a 26.2% BMI decrease. The Phase 2 SIGNAL trial showed oral bivamelagon achieved dose-dependent BMI reductions, up to 9.3%, while placebo groups gained weight. This signals breakthrough potential in a condition with limited treatments.